InvivoChem Cat #:V21294CAS #:112208-00-1Purity >=98%Description: Pam3CSK4 is a novel and potent TLR1/2 (toll-like receptor 1/2) agonist with an EC50 of 0.47 ng/mL for human TLR1/2. Pam3CSK4 is able to attenuate inflammatory responses caused by systemic infection of methicillin-resistant Staphylococcus aureus in mice. Combination of C and Pam3CSK4 enhances activation of B cells in vitro and boosts antibody responses to protein vaccines in vivo.
References:
1. IrvineKL, et al. The molecular basis for recognition of bacterial ligands atequine TLR2, TLR1 and TLR6. Vet Res. 2013 Jul 4; 44:50.
2. ChenY, et al. TLR2 agonist Pam3CSK4 enhances the antibacterial functions ofGM-CSF induced neutrophils to methicillin-resistant Staphylococcus aureus. Microb Pathog. 2019 May; 130:204-212.
3. Du X, et al. Systemic stimulation of TLR2 impairs neonatal mouse brain development. PLoS One. 2011 May 6; 6(5):e19583.
4. Frans G, van der Werff Ten Bosch J, Moens L, Gijsbers R, Changi-Ashtiani M, Rokni-Zadeh H, Shahrooei M, Wuyts G, Meyts I, Bossuyt X. Functional Evaluation of an IKBKG Variant Suspected to Cause Immunodeficiency Without Ectodermal Dysplasia. J Clin Immunol. 2017 Oct 10. doi: 10.1007/s10875-017-0448-9.